rentosertib
PulseAugur coverage of rentosertib — every cluster mentioning rentosertib across labs, papers, and developer communities, ranked by signal.
- 2026-09-18 product_launch Insilico Medicine's AI-discovered drug, rentosertib, begins Phase 3 clinical trials in China. source
- 2026-09-18 research_milestone Insilico Medicine's AI-discovered drug rentosertib has entered Phase 3 clinical trials in China. source
- 2026-09-07 research_milestone An experimental AI-developed drug for lung disease showed promise in reversing biological signs of aging during trials. source
- 2026-09-07 research_milestone AI-developed drug rentosertib shows early signs of slowing aging in a small clinical trial. source
- 2026-07-07 research_milestone Insilico Medicine's AI-discovered drug rentosertib has advanced to Phase III clinical trials for idiopathic pulmonary fibrosis. source
1 day(s) with sentiment data
-
AI-discovered drug rentosertib enters Phase 3 trials in China
Insilico Medicine, an AI drug discovery company, has advanced its drug rentosertib into Phase 3 trials in China for idiopathic pulmonary fibrosis. This marks a significant milestone as it is claimed to be the first AI-d…
-
OpenAI's GPT-6 Astra aces CSAT exam; AI drug shows anti-aging potential
OpenAI's new AI model, GPT-6 Astra, has achieved a perfect score on South Korea's CSAT exam, outperforming previous models like GPT-5.6, Claude, and Gemini in efficiency. Separately, an AI-designed drug developed by Ins…
-
AI-developed lung disease drug reverses biological aging signs
An experimental drug developed with artificial intelligence has demonstrated a remarkable ability to reverse biological signs of aging in patients with a lung disease. The AI-created drug, Rentosertib, not only targets …
-
AI-designed drug rentosertib shows early signs of slowing aging in trial
Insilico Medicine's AI-developed drug candidate, rentosertib, has shown early indications of slowing the aging process in a small clinical trial. The drug, designed to treat chronic lung disease, reduced biological age …
-
AI-designed drug reverses biological aging markers in early trial
Insilico Medicine's AI-designed drug, INS018_055, has shown promising results in a phase I clinical trial for idiopathic pulmonary fibrosis. The drug, rentosertib, appears to reverse biological aging markers, with six i…
-
AI accelerates idiopathic pulmonary fibrosis drug discovery timeline
AI played a significant role in the development of Rentosertib, a drug targeting idiopathic pulmonary fibrosis. The AI system identified TNIK as a novel target and optimized the molecular structure, compressing the disc…
-
First AI-designed drug Rentosertib enters Phase III trials
The first drug designed with significant AI involvement, Rentosertib, has advanced to Phase III clinical trials. AI was utilized to identify the drug's target, generate its molecular structure, and assist in the trial d…
-
AI News Roundup: Claude Opus 5 Benchmark, ChatGPT Adoption, and Regulatory Moves
Several AI developments are making headlines, including Anthropic's Claude Opus 5 achieving a new benchmark record on ARC-AGI-3. Meanwhile, OpenAI's ChatGPT is seeing widespread adoption by employees for tasks beyond th…
-
Insilico Medicine advances AI-discovered drug rentosertib to Phase III trials for IPF
Insilico Medicine is moving its AI-discovered drug, rentosertib, into Phase III clinical trials for idiopathic pulmonary fibrosis (IPF). The drug, which targets the TNIK protein, showed promising results in Phase II tri…
-
Takeda partners with Insilico Medicine for $600M AI drug discovery deal
Takeda Pharmaceutical Company has entered into a strategic collaboration with Insilico Medicine, utilizing AI for early-stage drug discovery. The deal, potentially worth up to US$600 million, grants Takeda exclusive wor…